Global Polio Vaccines Market Size By Type (IPV, OPV), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Polio Vaccines Market was valued at USD 1.89 billion in 2023 and is expected to reach USD 3.21 billion by 2031, expanding at a CAGR of 6.7% from 2023 to 2031. The market growth is primarily fueled by ongoing global immunization initiatives, rising awareness about disease prevention, and government-supported vaccination programs targeting polio eradication. Innovations in vaccine delivery, increased healthcare funding in emerging economies, and strategic stockpiling by health organizations further contribute to sustained demand.

Drivers:

1. Global Immunization Initiatives:

The WHO, UNICEF, and Gavi are among key global entities investing in polio eradication through structured immunization programs, which continue to significantly propel vaccine demand.

2. Government & NGO Support:

Large-scale vaccination campaigns supported by governments and non-governmental organizations in polio-endemic and high-risk regions help increase vaccination coverage.

3. Technological Advancements in Vaccines:

Development of improved Inactivated Polio Vaccines (IPVs), enhanced cold chain logistics, and needle-free delivery mechanisms are boosting vaccination uptake and efficiency.

Restraints:

1. Operational Challenges in Conflict Zones:

Political instability and conflict in some regions hinder vaccine distribution, cold chain maintenance, and accessibility to target populations.

2. Vaccine Hesitancy:

Misinformation and cultural resistance to vaccination in certain communities continue to pose a barrier to complete eradication.

Opportunity:

1. Expansion into Under-Vaccinated Regions:

Polio vaccine manufacturers and global health organizations can capitalize on low coverage regions such as parts of Africa and Southeast Asia.

2. Novel Delivery Technologies:

Innovations like microneedle patches and oral dissolving strips present significant opportunities to improve vaccine administration and compliance.

Market by System Type Insights:

The market is categorized into two major types: Oral Polio Vaccine (OPV) and Inactivated Polio Vaccine (IPV). In 2023, OPV dominated the global market due to its cost-effectiveness and ease of oral administration in mass immunization drives. However, IPV is gaining ground due to its safety profile and is expected to witness the fastest growth rate during the forecast period, driven by the global switch toward IPV-centric immunization strategies post-eradication goals.

Market by End-use Insights:

In terms of end use, Public Sector Programs (including government-led and NGO-supported campaigns) accounted for the largest share in 2023. The Private Healthcare Providers segment is also expanding, particularly in urban regions of middle-income countries, due to increasing healthcare awareness and voluntary immunization uptake.

Market by Regional Insights:

Asia-Pacific led the market in 2023, driven by extensive immunization campaigns in India, Pakistan, and Afghanistan—regions with historical polio prevalence. Africa is projected to exhibit the highest growth during the forecast period, as more countries transition from OPV to IPV and strengthen their public health systems. North America and Europe remain steady contributors due to ongoing infant immunization schedules and stockpile strategies.

Competitive Scenario:

Key players in the Global Polio Vaccines Market include Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India, Bilthoven Biologicals, China National Pharmaceutical Group Corporation (Sinopharm), and Bio Farma. These companies are actively involved in government collaborations, WHO prequalification programs, and expansion into emerging markets.

In 2023, Sanofi expanded its IPV production facility in France to meet growing global demand.

Serum Institute of India announced a new partnership with Gavi to supply polio vaccines to Africa and Asia through 2028.

In 2024, GlaxoSmithKline launched a heat-stable IPV formulation designed for use in remote and low-resource settings.

Scope of Work – Global Polio Vaccines Market

Key Market Developments:

Sanofi Pasteur enhanced its IPV production capacity in 2023, anticipating demand from Africa and Latin America.

Bio Farma, in collaboration with UNICEF, launched a low-cost IPV version specifically tailored for developing markets.

WHO announced a revised roadmap in 2024 for the complete cessation of OPV by 2028, fueling IPV market growth.

FAQs:

1) What is the current market size of the Global Polio Vaccines Market?

The market was valued at USD 1.89 billion in 2023.

2) What is the major growth driver of the Global Polio Vaccines Market?

The primary driver is the global push for polio eradication through mass immunization programs.

3) Which is the largest region during the forecast period in the Global Polio Vaccines Market?

Asia-Pacific held the largest market share in 2023, with Africa projected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Polio Vaccines Market?

The Oral Polio Vaccine (OPV) segment led the market in 2023.

5) Who are the key market players in the Global Polio Vaccines Market?

Major players include Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India, Sinopharm, and Bio Farma.